Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis

Autor: Ann-Marie Mallon, Dieter A. Häring, Frank Dahlke, Piet Aarden, Soroosh Afyouni, Daniel Delbarre, Khaled El Emam, Habib Ganjgahi, Stephen Gardiner, Chun Hei Kwok, Dominique M. West, Ewan Straiton, Sibylle Haemmerle, Adam Huffman, Tom Hofmann, Luke J. Kelly, Peter Krusche, Marie-Claude Laramee, Karine Lheritier, Greg Ligozio, Aimee Readie, Luis Santos, Thomas E. Nichols, Janice Branson, Chris Holmes

Publikováno v: BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-11 (2021)

Abstract Background Novartis and the University of Oxford’s Big Data Institute (BDI) have established a research alliance with the aim to improve health care and drug development by making it more efficient and targeted. Using a combination of the

Externí odkaz: https://doaj.org/article/d43dee580b834d6ca85817e178bae918

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5

Autor: Feng Huang, Fei Sun, Wei-Guo Wan, Li-Jun Wu, Ling-Li Dong, Xiao Zhang, Tae-Hwan Kim, Raj Sengupta, Ladislav Šenolt, Yi Wang, Hao-Min Qiu, Brian Porter, Sibylle Haemmerle, Li-Shao Guo

Publikováno v: Chinese Medical Journal, Vol 133, Iss 21, Pp 2521-2531 (2020)

Abstract. Background. Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies. Here, we present efficacy and safety results (52-week) of secukinumab in patients with AS fro

Externí odkaz: https://doaj.org/article/c81e1cedaca3470e9de3f15ec984e3eb

Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis

Autor: Thomas E. Nichols, Piet Aarden, E. Straiton, Sibylle Haemmerle, Aimee Readie, Greg Ligozio, Karine Lheritier, M.-C. Laramee, K. El Emam, Janice Branson, Daniel J. Delbarre, Christopher Holmes, Habib Ganjgahi, Soroosh Afyouni, C. H. Kwok, Stephen Gardiner, D. M. West, Peter Krusche, D. A. Haering, T. F. Hofmann, L. F. Kelly, Luis Santos, Ann-Marie Mallon, Frank Dahlke, Adam Huffman

Publikováno v: BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Medical Research Methodology

Background Novartis and the University of Oxford’s Big Data Institute (BDI) have established a research alliance with the aim to improve health care and drug development by making it more efficient and targeted. Using a combination of the latest st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a657dd557dc6dcb01b728c8f34b36c3c
https://doaj.org/article/d43dee580b834d6ca85817e178bae918

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

Autor: Ricardo Blanco, Sibylle Haemmerle, Anna Wiksten, Atul Deodhar, Stephen Hall, Eva Dokoupilova, Denis Poddubnyy, Hideto Kameda, Jürgen Braun, Hanno B. Richards, Marleen G H van de Sande, Alan Kivitz, Brian Porter

Publikováno v: Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & rheumatology (Hoboken, N.J.), 73(1), 110-120. John Wiley and Sons Ltd

Objective: To report the primary (1-year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA). Methods: A total of 555 patients were randomized (1:1:1) to receiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8649d6e281c51ca277b928b1a11047a
http://europepmc.org/articles/PMC7839589

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Autor: Ricardo Blanco, Sibylle Haemmerle, Atul Deodhar, Hideto Kameda, Stephen Hall, Marleen G H van de Sande, Helena Marzo-Ortega, Jürgen Braun, Denis Poddubnyy, Abhijit Shete, Anna Wiksten, Brian Porter, Hanno B. Richards, Lianne S. Gensler, Filip Van den Bosch

Publikováno v: Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-10 (2021)
Arthritis research & therapy, 23(1):231. BioMed Central
ARTHRITIS RESEARCH & THERAPY

Background To investigate the efficacy of secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) grouped by disease activity as assessed by C-reactive protein (CRP) levels and/or magnetic resonance imaging (MRI) score

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb5b1cc3bcb07a8d820e9d30c284473
http://europepmc.org/articles/PMC8418044